MedPath

Evaluation of the Prophylactic Efficacy of tDCS in Chronic Migraine

Not Applicable
Completed
Conditions
Chronic Migraine as Defined by Criteria of International Headache Society (IHS)
Interventions
Device: Transcranial direct current stimulation of the motor cortex
Device: simulation of Transcranial direct current stimulation of the motor cortex
Registration Number
NCT02120326
Lead Sponsor
University Hospital, Grenoble
Brief Summary

The purpose of this study is to determine whether TDCS is an effective prophylactic therapy of chronic migraine.

Detailed Description

Consenting patients will report on a book, all of their migraine attack for 1 month. Then they will be randomized to the active tDCS group or sham tDCS group. Patients will have one session of tDCS per day during the first week, then one session per week for a month and finally a session every 15 days for 1 month. After tDCS sessions, patients will be followed for 3 months. Throughout their participation in the study, patients will complete their migraine record (1month of base line before tDCS, 2 months during tDCS, 3 months after tDCS).

Patients will have 5 evaluation examinations:

* The first, one before tDCS,

* The second, 1 month after the beginning of tDCS

* The third, immediately after the end of tDCS

* The fourth, 1 month after the end of tDCS

* And the last one, 3 months after the end of tDCS.

The physician responsible for conducting tDCS sessions will make the randomization via a website.

The physician in charge of the evaluation examinations will don't know the allocated treatment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • Diagnosis of chronic migraine for more than 1 year
  • Stable treatment since 1 month
  • Frequency of migraine crisis is above 8 per month during last month
  • chronic migraine that has not been improved over the previous year by at least 3 different prophylactic treatments recommended and well conducted
  • Patient agreeing not to try other migraine prophylactic treatment, throughout the study
  • Patient's written consent
Exclusion Criteria
  • History of drug addiction, epilepsy, or severe head trauma with bone break
  • History of psychiatric illness (psychosis and severe cognitive disorders) may interfere with the proper conduct of the study
  • Presence of intracranial ferromagnetic material or an implanted stimulator
  • Introduction of a new treatment for less than a month
  • Pregnant women, parturient women, breast-feeding mother. Lack of effective contraception
  • Person not understanding the study protocol

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
active tDCSTranscranial direct current stimulation of the motor cortex-
simulated tDCSsimulation of Transcranial direct current stimulation of the motor cortex-
Primary Outcome Measures
NameTimeMethod
Comparison of the evolution of seizure frequency between the two groupsEvolution of seizure frequency since base line to 3 months after the end of tDCS
Secondary Outcome Measures
NameTimeMethod
Comparison of the evolution of seizure severity between the two groupsEvolution of seizure severity since base line to 3 months after the end of tDCS

Headache Impact Test 6 (HIT-6) questionnaire

Comparison of the evolution of crisis treatment use between the two groupsEvolution of crisis treatment use since base line until 3 months after the end of tDCS

Frequency of taking crisis treatment. After each crisis, taking crisis treatment will be noted by the patient on his migraine record book.

Comparison of the evolution of the disease impact between the two groupsEvolution of the disease impact since base line to 3 months after the end of tDCS

Migraine Disability Assessment Scale (MIDAS) scale

Comparison of the evolution of the patient satisfaction between the two groupsEvolution of the patient satisfaction since base line to 3 months after the end of tDCS

Clinical Global Impression (CGI) scale

Comparison of the evolution of the quality of life between the two groupsEvolution of the quality of life since base line until 3 months after the end of tDCS

Short Form 12 (SF-12) quality of life questionnaire

Comparison of the evolution of anxiety and depression levels between the two groupsEvolution of anxiety and depression levels since base line until 3 months after the end of tDCS

Hospital Anxiety and Depression scale (HAD) questionnaire

Trial Locations

Locations (2)

Grenoble University Hospital

🇫🇷

Grenoble, Isere, France

Hospital of Voiron

🇫🇷

Voiron, Isere, France

© Copyright 2025. All Rights Reserved by MedPath